Search results
Showing results for
Twelve outstanding articles have been shortlisted for this year’s Max Perutz Science Writing Award, the MRC’s annual writing competition. The shortlist includes our DPhil student Magda Mareckova (pictured).
OxLuPIn Study
The OxLuPIn study (Oxford Luteal Dysfunction and Placental Insufficiency) is looking for women aged 16 years or older, who are less than 8 weeks’ pregnant, to help us understand early pregnancy and how to better predict complications such as high blood pressure later on.
Latest news
Oxford researchers develop wearable ultrasound patch for continuous pregnancy monitoring
26 May 2026
New technology could help identify fetal complications earlier in high-risk pregnancies. Researchers at the University of Oxford and collaborators have helped develop a wearable ultrasound patch capable of continuously monitoring fetal wellbeing during pregnancy, offering a potential new approach to identifying complications earlier in high-risk pregnancies.
Targeted Removal of sFlt-1 in Very Preterm Preeclampsia: A Promising First-in-Human Pilot Study
15 May 2026
A first-in-human pilot study, published in Nature Medicine, suggests that selectively removing a placenta-derived protein called soluble Fms-like tyrosine kinase 1 (sFlt-1) from the blood may be a safe and feasible way to help manage very preterm preeclampsia.
Oxford to lead Europe's largest miscarriage research centre in partnership with Tommy's
13 May 2026
The Nuffield Department of Women's & Reproductive Health is proud to announce that it is now leading Tommy's National Centre for Miscarriage Research, alongside existing partners: the University of Birmingham, the University of Warwick, and Imperial College London.
Ovarian Cancer Awareness Day 2026 highlights the need for earlier detection and better outcomes
8 May 2026
Today, on World Ovarian Cancer Day, we recognise the impact ovarian cancer has on women and families worldwide, and the urgent need for earlier diagnosis, improved treatment, and better survival outcomes. The day also highlights the importance of continued research to improve understanding of ovarian cancer biology, diagnosis, treatment, and patient outcomes. High-grade serous ovarian cancer is the most common subtype of ovarian cancer, with many patients diagnosed at an advanced stage. Survival outcomes remain closely linked to the stage at which the disease is diagnosed.